Cardiovascular Risk in Thai MASLD Patients: Coronary Calcium Scores
Official title: Association of Cardiovascular Disease Risk Assessment With Coronary Artery Calcium Score in Thai Patients With Metabolic Dysfunction-Associated Steatotic Liver Disease
Run by Mahidol University · NCT07865936 · Data updated 2026-11-12
This study tests how well common cardiovascular risk tools align with coronary calcium scores in Thai adults with MASLD who have no heart symptoms.
Quick facts
| Study type | Observational |
|---|---|
| Ages | 35 Years to 75 Years |
| Sex | All |
| Enrollment | 251 (estimated) |
| Sponsor | Mahidol University Academic / other |
| Locations | 1 site (Bangkok, Bangkoknoi) |
| Status | Recruiting |
| Started | June 24, 2026 |
| Main results expected | May 23, 2027 |
| Study ends | June 23, 2036 |
| Registry record updated | October 8, 2026 |
| Trial ID | NCT07865936 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Ideal candidates are asymptomatic Thai adults with MASLD diagnosed by ultrasound or FibroScan CAP, plus available fibrosis and metabolic data.
✕Probably not a fit
Patients without MASLD, with existing cardiovascular disease, or insufficient data may derive little or no benefit from this work.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
This observational study in Bangkok will analyze how existing cardiovascular risk calculators relate to coronary artery calcium scores in patients with MASLD. Researchers will collect clinical data, metabolic parameters, and liver disease measurements to see if risk scores reflect subclinical atherosclerosis detected by CAC scoring. The goal is to improve cardiovascular risk stratification for MASLD patients in Thailand. Results may help identify which patients would benefit most from preventive care based on CAC findings. The study does not involve an intervention and will use noninvasive imaging and standard laboratory tests.
Why it matters
Potential benefit: If successful, clinicians may better identify MASLD patients at higher cardiovascular risk who could benefit from targeted prevention efforts.
How similar studies have gone: Previous work shows CAC scoring is predictive of events in various populations, but data in MASLD patients, especially in Thailand, are limited.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: * Asymptomatic * Diagnosed MASLD by: Ultrasound showing fatty liver, or FibroScan CAP ≥ 248 dB/m * Available liver fibrosis assessment (FIB-4, APRI) * Complete clinical and laboratory data required for cardiovascular risk assessment Exclusion Criteria: * History of myocardial infarction, PCI, or CABG * History of stroke or peripheral arterial disease * History of heart failure, RV dysfunction, or pulmonary hypertension * Chronic hepatitis B or C * Autoimmune hepatitis, Wilson's disease, hemochromatosis * Alcohol intake \>30 g/day (men) or \>20 g/day (women) * CKD stage 4-5 or ESRD * Advanced cancer * Pregnancy
Where it's running
-
Faculty of Medicine Siriraj Hospital, Mahidol University
Bangkok, Bangkoknoi, Thailand Recruiting
Study contacts
- Study coordinator: Assoc. Prof. Watcharasak Chotiyaputta, M.D.
- Email: watcharasak.cho@mahidol.ac.th
- Phone: +66 85-125-5489
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
Understanding aldosterone in hypertension among Kaiser Permanente members
This is an observational program to see how aldosterone relates to high blood pressure in adults with hypertension, using data from Kaiser Permanente members in Northern California.
-
ALN-PNP with or without a GLP-1/GIP receptor agonist in adults with PNPLA3-related MASLD
This study tests ALN-PNP, with or without tirzepatide, to see if it can reduce liver fat in adults with PNPLA3-related MASLD.
-
Monitoring progression of chronic cardiovascular conditions
This project will collect wearable physiologic data from adults with cardiovascular conditions to see how their heart disease changes over time.
-
Ferumoxytol-enhanced heart MRI to find calcified coronary arteries
This research will see if ferumoxytol-enhanced heart MRI can detect calcified coronary arteries in adults who already have calcification on coronary CT angiography.
-
Initial dual oral therapy versus monotherapy for PAH with cardiovascular comorbidities
This trial will test whether starting both tadalafil and ambrisentan together works better than tadalafil alone for people newly diagnosed with pulmonary arterial hypertension who have at least two heart or vascular health problems.
-
Cardiovascular effects of gender-affirming hormones in adults
This project tests whether masculinizing or feminizing gender-affirming hormone therapy changes heart and blood vessel health in transgender adults who have been on hormones for at least 12 months.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.